Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease (Jan 2022)

Use of Pulmonary Arterial Hypertension Therapies in Patients with a Fontan Circulation: Current Practice Across the United Kingdom

  • Andrew Constantine,
  • Konstantinos Dimopoulos,
  • Petra Jenkins,
  • Robert M. R. Tulloh,
  • Robin Condliffe,
  • Katrijn Jansen,
  • Natali A. Y. Chung,
  • James Oliver,
  • Helen Parry,
  • Samantha Fitzsimmons,
  • Niki Walker,
  • Stephen John Wort,
  • Vasilios Papaioannou,
  • Kate von Klemperer,
  • Paul Clift

DOI
https://doi.org/10.1161/JAHA.121.023035
Journal volume & issue
Vol. 11, no. 1

Abstract

Read online

Background The Fontan circulation is a successful operative strategy for abolishing cyanosis and chronic volume overload in patients with congenital heart disease with single ventricle physiology. “Fontan failure” is a major cause of poor quality of life and mortality in these patients. We assessed the number and clinical characteristics of adult patients with Fontan physiology receiving pulmonary arterial hypertension (PAH) therapies across specialist centers in the United Kingdom. Methods and Results We identified all adult patients with a Fontan‐type circulation under active follow‐up in 10 specialist congenital heart disease centers in England and Scotland between 2009 and 2019. Patients taking PAH therapies were matched to untreated patients. A survey of experts was also performed. Of 1538 patients with Fontan followed in specialist centers, only 76 (4.9%) received PAH therapies during follow‐up. The vast majority (90.8%) were treated with a phosphodiesterase‐5 inhibitor. In 33% of patients, PAH therapies were started after surgery or during hospital admission. In the matched cohort, treated patients were more likely to be significantly limited, have ascites, have a history of protein‐losing enteropathy, or receive loop diuretics (P<0.0001 for all), also reflecting survey responses indicating that failing Fontan is an important treatment target. After a median of 12 months (11–15 months), functional class was more likely to improve in the treated group (P=0.01), with no other changes in clinical parameters or safety issues. Conclusions PAH therapies are used in adult patients with Fontan circulation followed in specialist centers, targeting individuals with advanced disease or complications. Follow‐up suggests stabilization of the clinical status after 12 months of therapy.

Keywords